Moorestown, New Jersey, United States

7322321334

seeking biotech alpha

seeking biotech alpha 1/20/2020 the heart of biotech™

seeking biotech alpha 1/20/2020 the heart of biotech™

seeking biotech alpha 1/20/2020 the heart of biotech™seeking biotech alpha 1/20/2020 the heart of biotech™seeking biotech alpha 1/20/2020 the heart of biotech™
image239
Thank you for visiting

Welcome to BiOTECHVORTEX™

The www.biotechvortex.com section of the site I started when I started seeing the connections, links, partnerships, new technologies and mergers that were taking place in the biotech sector.  Vortexes are powerful and transformational centers of energy.  Thank you for visiting www.biotechvortex.com.  .

BiotechVortex™

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing

image240

 

Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer

Mon January 13, 2020 4:20 PM|PR Newswire|About: AMGN

Collaborations With Guardant Health and QIAGEN Will Develop Blood- and Tissue-Based Companion Diagnostics For Investigational KRAS(G12C) Inhibitor AMG 510

KRAS G12C is Present in 13% of Non-Small Cell Lung Cancers With no Approved Targeted Treatments

PR Newswire

THOUSAND OAKS, Calif., Jan. 13, 2020 /PRNewswire/ -- Amgen (AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. 


 https://www.amgen.com/ 


 https://www.prnewswire.com/news-releases/amgen-announces-global-diagnostic-collaborations-to-expand-molecular-testing-for-patients-with-non-small-cell-lung-cancer-300986051.html 

IDA Ireland

image241

 

IDA Ireland

Operations in Ireland

 Pfizer has IDA-supported facilities at five sites in Ireland that employ 3,500 people. It is the largest pharmaceutical sector investor and employer. From an initial investment of €10 million in 1969, Pfizer's total investment in Ireland now stands at nearly €8 billion.  

https://www.idaireland.com/how-we-help/case-studies/pfizer 

 GSK employs 1,450 people in Ireland and first established operations here in 1975. It has two manufacturing operations in Dungarvan and is the largest employer in the town with almost 700 staff; it has a third manufacturing operation, where it develops and produces a range of bulk pharmaceuticals, together with R&D and European Trading operations in Cork; and in Dublin there are Sales and Marketing functions. 

https://www.idaireland.com/how-we-help/case-studies/gsk 

 In 1997, Takeda, the largest pharmaceutical company in Japan, established a Formulation Plant in Bray, Wicklow, for the manufacture of three of the company’s blockbuster drugs (Prevacid, Blopress and Actos). The establishment of this facility was paramount to Takeda’s strategy in responding to expanding growth in the European and US markets. This plant has significantly expanded its operation since inception and operates on a 24 hour/7 day basis. 

https://www.idaireland.com/how-we-help/case-studies/takeda 


WuXi Bio to acquire Bayer facility

image242

 

WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

Wed January 15, 2020 7:26 PM|PR Newswire|About: WXXWY

  • First drug product facility in Europe to complement WuXi Biologics' existing commercial manufacturing capacities
  • WuXi Biologics (WXXWY) will be the back-up manufacturer for Kovaltry™ of Bayer

SHANGHAI and LEVERKUSEN, Germany, Jan. 15, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK)


 https://www.wuxibiologics.com/ 


 https://www.prnewswire.com/news-releases/wuxi-biologics-and-bayer-enter-into-an-acquisition-agreement-on-a-drug-product-plant-in-germany-300987934.html 


 https://seekingalpha.com/symbol/WXXWY 


Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

image243

 

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

Thu January 16, 2020 8:00 AM|Business Wire|About: A

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) is collaborating with researchers at two UK universities


 https://www.agilent.com/ 


 https://www.sheffield.ac.uk/ 


 https://www.manchester.ac.uk/ 


 https://www.businesswire.com/news/home/20200116005137/en/ 

 

Agilent Collaborates with University Researchers Investigating Risk Factors for Eczema

SANTA CLARA, Calif. , January 16, 2020 

 https://www.agilent.com/about/newsroom/presrel/2020/16jan-ca20002.html 

BiotechVortex™

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche

image244

 

Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology

Fri January 10, 2020 7:00 AM|GlobeNewswire

  • Amunix to receive $40 million in upfront payment and may receive up to $1.5 billion in development and sales milestones

  • Roche to utilize XTEN, Amunix’s clinically validated therapeutic half-life extension technology, to discover and develop novel therapeutics

MOUNTAIN VIEW, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”),


 https://www.amunix.com/ 





LogicBio Therapeutics Announces Collaboration with Takeda

image245

 

LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome

Fri January 10, 2020 7:00 AM|GlobeNewswire|About: LOGC

– LB-301 is a recombinant AAV vector with a UGT1A1 gene leveraging GeneRide™ genome editing platform for the treatment of Crigler-Najjar syndrome –

– The collaboration agreement grants Takeda (TKPHF) an exclusive option to negotiate an exclusive, worldwide license to LogicBio’s LB-301 program –

– Crigler-Najjar syndrome is the second indication to be pursued using GeneRide™ platform –

CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (LOGC),


 https://www.embopress.org/doi/full/10.15252/emmm.201707601 


 https://www.logicbio.com/ 


 https://seekingalpha.com/symbol/LOGC 



Almirall and WuXi Biologics Sign Strategic Collaboration Agreement

image246

 

Almirall and WuXi Biologics Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

Thu January 9, 2020 1:11 PM|PR Newswire|About: WXXWY

- The agreement is another in a series of strategic partnerships in which Almirall reinforces its position as a leader in the promotion for skin healthcare

- This collaboration showcases the power and versatile applications of WuXiBody™ in multiple therapeutic areas, including the development of First-in-Class molecules in dermatology

PR Newswire

BARCELONA, Spain, Jan. 9, 2020 /PRNewswire/ -- Almirall, S.A. (LBTSF) (ALM) and WuXi Biologics (WXXWY) ("WuXi Bio") (2269.HK)


 https://www.almirall.com/ 


 https://seekingalpha.com/symbol/WXXWY 


 https://www.prnewswire.com/news-releases/almirall-and-wuxi-biologics-sign-strategic-collaboration-agreement-for-multiple-bispecific-antibodies-targeting-dermatology-diseases-300984520.html 


 https://www.wuxibiologics.com/ 



Swiss Biotech Association

image247

 

Global Innovation Index 2019: Switzerland is the world’s most-innovative country

  • Wednesday, July 24, 2019 @ 12:00 am

Switzerland is the world’s most-innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the 2019 edition of the Global Innovation Index (GII), which also identifies regional leaders India, South Africa, Chile, Israel and Singapore, with China, Vietnam and Rwanda topping their income groups.

 Switzerland is the world’s most innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the GII 2019.   https://www.wipo.int/global_innovation_index/en/2019/index.html  


 

Contact

Swiss Biotech Association
Stauffacherstrasse 16
8004 Zürich
T: +41 44 455 56 78
E-mail

Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal

image248

 

Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal

Fri January 10, 2020 7:00 AM|GlobeNewswire|About: SRNE

SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE)


 https://seekingalpha.com/symbol/SRNE 


 https://sorrentotherapeutics.com/pipeline/ 

Janssen Expands Research & Development Presence with Major Investment in South San Francisco

image249

 

Janssen Expands Research & Development Presence with Major Investment in South San Francisco

Fri January 10, 2020 4:00 PM|Business Wire|About: JNJ

Investment delivers on overall strategy to expand pharmaceutical research and development footprint and enhance presence in critical innovation hotbed

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ


 https://www.janssen.com/ 


 https://www.jnj.com/ 


 https://www.businesswire.com/news/home/20200110005545/en/ 

BiotechVortex™

Evotec And Bristol-Myers Squibb Expand iPSC Collaboration

image250

 

Evotec And Bristol-Myers Squibb Expand iPSC Collaboration

Tue January 7, 2020 1:40 AM|Accesswire|About: EVTCY

  • ADDING CELL TYPES SUPPORTS DISCOVERY OF DISEASE-MODIFYING THERAPIES FOR NEURODEGENERATIVE DISEASES AND TRIGGERS US$ 6 M PAYMENT TO EVOTEC

HAMBURG, GERMANY / ACCESSWIRE / January 7, 2020 / Evotec SE (EVOTF) (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company (NYSE:BMY) following the decision to expand the collaboration to include additional cell lines.

Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016 


 https://www.evotec.com/en 


 https://seekingalpha.com/symbol/EVTCY 

Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma

image251

 

Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma

Wed January 8, 2020 8:15 AM|Business Wire|About: AZN, VCYT

Agreement enabled by Veracyte (VCYT) acquisition of NanoString diagnostics assets for global expansion

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte (Nasdaq: VCYT)


 https://www.businesswire.com/news/home/20200108005252/en/ 


 https://www.veracyte.com/ 


 https://www.acerta-pharma.com/ 


 

Veracyte collaborates with Acerta Pharma

Jan. 8, 2020 8:32 AM ET|About: Veracyte, Inc. (VCYT)|By: , SA News Editor 

 https://seekingalpha.com/news/3530376-veracyte-collaborates-acerta-pharma 

Medtronic Acquires Stimgenics, Pioneer of DTM™, a Novel Spinal Cord Stimulation Therapy

image252

 

Medtronic Acquires Stimgenics, Pioneer of DTM™, a Novel Spinal Cord Stimulation Therapy

Wed January 8, 2020 5:19 PM|GlobeNewswire|About: MDT

Randomized Control Trial Results to be Presented at NANS Jan. 23-26 in Las Vegas; New, Proprietary Differential Target Multiplexed (DTM) Therapy Available on Medtronic Intellis Spinal Cord Stimulation Platform

DUBLIN, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)


 https://clinicaltrials.gov/ct2/show/NCT03606187 


 https://www.medtronic.com/us-en/index.html 


 https://www.cmocro.com/company/Stimgenics%2C+LLC/index.html 


Pfizer teams up with eFFECTOR Therapeutics in cancer

image254

 

Pfizer teams up with eFFECTOR Therapeutics in cancer

Jan. 9, 2020 9:36 AM ET|About: Pfizer Inc. (PFE)|By: , SA News Editor 


 https://effector.com/ 


 https://seekingalpha.com/symbol/TXMD 


 

Pfizer Joins With EFFECTOR To Develop Therapy For Treatment-refractory Cancers

CONTRIBUTORRTTNews.com  RTTNewsPUBLISHEDJAN 9, 2020 8:35AM EST 

 https://www.nasdaq.com/articles/pfizer-joins-with-effector-to-develop-therapy-for-treatment-refractory-cancers-2020-01-09 



BiotechVortex™

human CD38 antibody (TJ202/MOR202)

image256

 

I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Phase 2 Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

Fri January 3, 2020 8:30 AM|PR Newswire

SHANGHAI, Jan. 3, 2020 /PRNewswire/ -- I-Mab Biopharma 


 https://www.prnewswire.com/news-releases/i-mab-biopharma-announces-dosing-of-first-patient-in-a-pivotal-phase-2-study-of-tj202mor202-in-multiple-myeloma-in-mainland-china-300980844.html 


 http://www.i-mabbiopharma.com/en/ 


 http://www.i-mabbiopharma.com/en/Partnering.aspx#row2 

Pulmatrix = Kinase Inhibitor Licensing Agreement w/ Lung Cancer Initiative at Johnson & Johnson

image257

 

Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson

Thu January 2, 2020 8:51 AM|PR Newswire|About: PULM

LEXINGTON, Mass., Jan. 2, 2020 /PRNewswire/ -- Pulmatrix, Inc. (PULM) (NASDAQ: PULM)


 https://www.prnewswire.com/news-releases/pulmatrix-announces-kinase-inhibitor-licensing-agreement-with-lung-cancer-initiative-at-johnson--johnson-300980456.html 


 http://www.pulmatrix.com/pipeline.html 



Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

image258

 

Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

Mon January 6, 2020 6:30 AM|Business Wire|About: MRK

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)


 https://www.businesswire.com/news/home/20200106005313/en/ 


 https://www.taiho.co.jp/en/ 


 https://astx.com/ 


 https://www.otsuka.co.jp/en/ 


Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos

image259

 

Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

Thu July 25, 2019 3:00 AM|PR Newswire|About: VAR 


 

HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

Karolinska University Hospital Solna Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

Thu July 25, 2019 3:00 AM|PR Newswire|About: VAR 

NEWS PROVIDED BY Varian   Jul 25, 2019, 03:00 ET

 PALO ALTO, Calif. and STOCKHOLM, July 25, 2019 /PRNewswire/ -- Varian (NYSE: VAR) announced that the Karolinska University Hospital Solna in Sweden is the first hospital in Scandinavia to deliver High Dose Rate (HDR) brachytherapy treatments using the new Bravos™ afterloader system 

http://www.varian.com  

https://seekingalpha.com/article/4277633-varian-medical-systems-inc-2019-q2-results-earnings-call-slides 

https://www.varian.com/oncology/products/treatment-delivery/brachytherapy-afterloaders-applicators/bravos 

https://www.prnewswire.com/news-releases/karolinska-university-hospital-solna-delivers-hdr-brachytherapy-cancer-treatments-with-varian-bravos-afterloader-system-300889555.html 


 

 Karolinska University Hospital is one of Europe’s premier health facilities. Together with the world-respected Karolinska Institutet, we lead in development and medical break-throughs.  

https://www.karolinska.se/?splitoption=splitdecision 

Infliximab biosimilar

image260

 

Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China

Mon January 6, 2020 7:00 AM|GlobeNewswire|About: SRNE

SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (SRNE) announced today that its partner Mabpharm (HK:2181)


 https://sorrentotherapeutics.com/pipeline/ 


 https://sorrentotherapeutics.com/ 


 http://www.mabpharm.cn/en/index.php 


BiotechVortex™

AZD7325, a novel α2/3–subtype-selective GABA A positive allosteric modulator (“PAM”)

image262

 

Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

Mon December 23, 2019 8:30 AM|GlobeNewswire|About: AZN, FBIOGlobeNewswire

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (FBIO) (“Fortress”) today announced that Baergic Bio, Inc. 


 https://www.fortressbiotech.com/programs 


 

Fortress Bio in-licenses rights for AstraZeneca's AZD7325

Dec. 23, 2019 8:52 AM ET|About: AstraZeneca PLC (AZN)|By: , SA News Editor  

 https://seekingalpha.com/news/3528108-fortress-bio-in-licenses-rights-for-astrazenecas-azd7325 

Gilead & Eisai Enter Into Agreement in Japan for the Rheumatoid Arthritis Therapy Filgotinib

image265

 

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval

Tue December 24, 2019 1:00 AM|Business Wire|About: GILD

-- Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohn’s Disease and Psoriatic Arthritis --

FOSTER CITY, Calif. & TOKYO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Eisai Co., Ltd. (Tokyo, Japan)


 https://www.gilead.com/news-and-press/press-room/press-releases/2019/12/gilead-and-eisai-enter-into-agreement-in-japan-for-the-copromotion-of-the-investigational-rheumatoid-arthritis-therapy-filgotinib-pending-regulatory 


 https://www.businesswire.com/news/home/20191223005626/en/ 



Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb)

 

Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.

Mon December 30, 2019 4:05 PM|PR Newswire|About: JNJ

HORSHAM, Pa., Dec. 30, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ)


 https://www.janssen.com/ 


 https://www.prnewswire.com/news-releases/janssen-announces-completion-of-acquisition-of-investigational-bermekimab-from-xbiotech-inc-300979941.html 


 XBiotech is committed to advancing its robust pipeline of potential breakthrough antibody therapies. Each of the Company’s targeted antibody candidates were discovered and developed using XBiotech’s proprietary True Human™ technology. 

 http://www.xbiotech.com/clinical/index.php 


 XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen 

 http://investors.xbiotech.com/news-releases/news-release-details/xbiotech-closes-sale-true-human-antibody-bermekimab-janssen 

BiotechVortex™

Medtronic and ChristianaCare Collaborate

image267

 

Medtronic and ChristianaCare Collaborate to Improve Patient Outcomes and Reduce Cost of Care in Delaware

Mon December 16, 2019 8:00 AM|GlobeNewswire|About: MDT

Value-Based Healthcare Collaboration Designed to Help ChristianaCare 
Apply Right Therapies to Patients Who May Benefit Most

DUBLIN and NEW CASTLE, Del., Dec. 16, 2019 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) and ChristianaCare 


 https://www.medtronic.com/us-en/index.html 


 

 https://christianacare.org/ 

Alexion = Two Additional GalXC™ RNAi Programs -Mediated Targets = Collaboration w/ Dicerna™

image268

 

Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™

Mon December 16, 2019 8:00 AM|Business Wire|About: ALXN, DRNA

– Option Exercise Triggers $20 Million Payment to Dicerna –

BOSTON & LEXINGTON, Mass.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (ALXN) (NASDAQ:ALXN) and Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA)


 https://www.businesswire.com/news/home/20191216005150/en/ 


 https://alexion.com/ 


 https://alexion.com/research-development/pipeline 


 https://dicerna.com/ 



Leronlimab

image270

 

CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV

Tue December 17, 2019 4:36 PM|GlobeNewswire|About: CYDY

In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera will also make an investment in CytoDyn (CYDY) of $4 million in the form of registered CytoDyn common stock

CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications

VANCOUVER, Washington and NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc., (“CytoDyn”) and Vyera Pharmaceuticals, LLC (“Vyera”)


 https://www.cytodyn.com/ 


 https://www.cytodyn.com/pipeline/hiv 


 https://www.vyera.com/ 



Stealth Autoguide™ System

image271

 

Medtronic Expands Surgical Synergy(SM) with FDA Clearance of the Stealth Autoguide™ System for Cranial Procedures

Wed December 18, 2019 7:00 AM|GlobeNewswire|About: MDT

Robotic Trajectory Guidance Platform Integrates Multiple Enabling Technologies to Support Complex Cranial Procedures

DUBLIN, Dec. 18, 2019 (GLOBE NEWSWIRE) --  Medtronic plc (MDT)


 https://www.medtronic.com/us-en/index.html 


Arcus Biosciences, in Collaboration with Genentech

image272

 

Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers

Wed December 18, 2019 4:05 PM|Business Wire|About: RCUS

Collaboration leverages Genentech’s MORPHEUS studies to accelerate development of AB928, a potential best-in-class therapy targeting the adenosine axis to stimulate immune responses against cancer

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (RCUS)


 https://www.arcusbio.com/ 


 https://www.businesswire.com/news/home/20191218005727/en/ 

 

Arcus Bio to collaborate with Roche on two cancer studies

Dec. 18, 2019 4:23 PM ET|About: Arcus Biosciences, Inc. (RCUS)|By: , SA News Editor  

 https://seekingalpha.com/news/3527252-arcus-bio-to-collaborate-roche-on-two-cancer-studies 


BiotechVortex™

Kevzara® (sarilumab) and Praluent® (alirocumab)

image276

 

Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

Tue December 10, 2019 8:30 AM|GlobeNewswire|About: SNY

Sanofi (SNY) and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

PARIS (FRANCE) AND TARRYTOWN, NY - December 10, 2019 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) 


 December 10, 2019 at 8:29 AM EST Back

REGENERON AND SANOFI ANNOUNCE INTENT TO RESTRUCTURE ANTIBODY COLLABORATION FOR KEVZARA® (SARILUMAB) AND PRALUENT® (ALIROCUMAB)

TARRYTOWN, N.Y. and PARIS, Dec. 10, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi

 https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-intent-restructure-antibody 

Merck to Acquire ArQule, Advancing Leadership in Oncology

image277

 

Merck to Acquire ArQule, Advancing Leadership in Oncology

Mon December 9, 2019 6:45 AM|Business Wire|About: ARQL, MRK

Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies

KENILWORTH, N.J. & BURLINGTON, Mass.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (ARQL)


 https://www.businesswire.com/news/home/20191209005234/en/ 



Takeda Partners with MiTest Health

image278

Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn's Disease Management

Fri December 13, 2019 3:05 PM|PR Newswire|About: TAKPR Newswire

LEXINGTON, Mass., Dec. 13, 2019 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A. (TSE: 4502) (NYSE:TAK) ("Takeda (TKPHF)") and MiTest Health LLC


 https://www.prnewswire.com/news-releases/takeda-partners-with-mitest-health-to-launch-innovative-disease-risk-prediction-tool-to-redefine-crohns-disease-management-300974776.html 


BiotechVortex™

Neurocrine Biosciences & Xenon Pharmaceuticals Announce Agreement to Develop Treatments for Epilepsy

image279

 

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Mon December 2, 2019 7:30 AM|PR Newswire|About: NBIX, XENE

Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Across All Licensed Products, as well as Option to Co-Fund XEN901

PR Newswire

SAN DIEGO and BURNABY, British Columbia, Dec. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) and Xenon Pharmaceuticals Inc. (XENE)


 https://www.xenon-pharma.com/product-pipeline/ 


 https://www.neurocrine.com/pipeline/pipeline-overview/ 



Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)

image281


  

FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List

Mon December 2, 2019 7:00 AM|GlobeNewswire|About: FGEN

SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FGEN)


 https://www.fibrogen.com/ 


 FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List

SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) 

 https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-roxadustat-inclusion-chinas-national 


 https://seekingalpha.com/news/3522929-fibrogen-3-percent-reimbursement-roxadustat-china 

Reblozyl® (luspatercept-aamt)

image282

 

Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes

Tue December 3, 2019 7:38 AM|Business Wire|About: BMY, XLRN

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) (NYSE: BMY) and Acceleron Pharma Inc. (XLRN


 https://media.celgene.com/content/uploads/reblozyl-pi.pdf 


 https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-and-acceleron-pharma-announce-fda-advisor 


 http://acceleronpharma.com/science-pipeline/pipeline/ 


 https://www.businesswire.com/news/home/20191203005566/en/ 


 https://seekingalpha.com/news/3523331-fda-ad-com-set-for-bristol-myers-luspatercept-for-mds 


 http://acceleronpharma.com/ 

NanoString Announces Exclusive License of nCounter Diagnostic Assets and Rights to Veracyte

image284



NanoString Announces Exclusive License of nCounter Diagnostic Assets and Rights to Veracyte

Tue December 3, 2019 5:00 PM|Business Wire|About: NSTG

Creates Potential for Significantly Expanded Test Menu

Sharpens NanoString’s Strategic Focus on Rapidly Growing Research Business Including Recent Launch of GeoMx Digital Spatial Profiler

Strengthens Financial Profile through Capital Infusion and Streamlined Operations

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NSTG


 https://www.businesswire.com/news/home/20191203006031/en/ 


 https://www.nanostring.com/ 


 https://seekingalpha.com/news/3523662-nanostring-announces-exclusive-license-of-ncounter-diagnostic-assets-to-veracyte 


 https://www.veracyte.com/ 



BiotechVortex™

Moderna (MRNA) & Harvard University

image285

 

Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University

September 26, 2019 at 8:00 AM EDTPDF Version

Collaboration seeks to explore fundamental immunological processes and identify potential therapeutic opportunities  

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2019-- Moderna, Inc., (Nasdaq: MRNA)

 https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-mrna-immunotherapy-research-collaboration 


 September 26, 2019

Harvard University establishes mRNA immunotherapy research collaboration with Moderna

Collaboration seeks to explore fundamental immunological processes and identify potential therapeutic opportunities

Cambridge, Mass. - September 26, 2019 Harvard University

 https://otd.harvard.edu/news/harvard-university-establishes-mrna-immunotherapy-research-collaboration-wi 


 

Moderna collaborates with Harvard University for immunology programs

Sep. 26, 2019 8:42 AM ET|About: Moderna, Inc. (MRNA)|By: , SA News Editor 

 https://seekingalpha.com/news/3502018-moderna-collaborates-harvard-university-immunology-programs 


 
https://www.modernatx.com/pipeline  


Dragonfly Therapeutics Announces Collaboration with AbbVie

image286

 

Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

Wed November 20, 2019 8:00 AM|PR Newswire|About: ABBV

Dragonfly will use its TriNKET™ platform to develop drug candidates directed to multiple targets for autoimmune disorders, and oncology.  AbbVie receives exclusive options to license a number of Dragonfly's natural killer (NK) cell engager immunotherapies.

WALTHAM, Mass., Nov. 20, 2019 /PRNewswire/ -- Dragonfly Therapeutics


 https://www.dragonflytx.com/ 


 https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-collaboration-with-abbvie-for-autoimmune-diseases-and-oncology-300961954.html 


 https://www.dragonflytx.com/about-us 

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration

image288

 

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

Thu November 21, 2019 4:00 AM|GlobeNewswire|About: ABBV, HARP 

 SOUTH SAN FRANCISCO, Calif. and NORTH CHICAGO, Ill., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc. (ABBV


 https://www.globenewswire.com/NewsRoom/AttachmentNg/7e618bf2-6d57-40b3-bdd8-00765a1ed497 


 https://www.harpoontx.com/pipeline/ 


 https://news.abbvie.com/news/press-releases/harpoon-therapeutics-and-abbvie-announce-licensing-and-option-collaboration-to-advance-hpn217-harpoons-bcma-targeting-tritac-and-expand-existing-discovery-collaboration.htm 

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene

image289

 

Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

Fri November 22, 2019 2:30 AM|Business Wire|About: ZYME

SINGAPORE--(BUSINESS WIRE)-- Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics


 https://www.businesswire.com/news/home/20191121005148/en/ 


 

Zymeworks reports updated ZW25 Phase 1 data in HER2-expressing cancers

Nov. 22, 2019 7:08 AM ET|About: Zymeworks Inc. (ZYME)|By: , SA News Editor  

 https://seekingalpha.com/news/3521477-zymeworks-reports-updated-zw25-phase-1-data-her2-expressing-cancers 

BiotechVortex™

Bristol-Myers Squibb and Pfizer

image291

 

Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals

Fri November 15, 2019 9:00 AM|Business Wire|About: PFE

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- The Bristol-Myers Squibb-Pfizer Alliance 


 https://www.businesswire.com/news/home/20191115005062/en/ 



 https://my.clevelandclinic.org/health/articles/13398-know-your-risk-factors-for-stroke 



Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4B

 

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion

Mon August 26, 2019 6:30 AM|Business Wire|About: AMGN, BMY, CELG

Agreement Contingent on FTC Consent Decree and Closing of Pending Bristol-Myers Squibb-Celgene Merger

Pending Bristol-Myers Squibb-Celgene Merger Expected to Close by End of 2019

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) announced today that Celgene Corporation (CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (AMGN) under which Amgen would acquire the global rights to OTEZLA® (apremilast) for $13.4 billion in cash.


 https://www.businesswire.com/news/home/20190826005247/en/ 


 https://seekingalpha.com/news/3519945-ftc-board-bristol-myers-celgene-tie-otezla-sale 



image292

 

Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

Mon November 18, 2019 6:00 AM|Business Wire|About: DRNA

– Collaboration to Explore Liver Cell Targets Using Dicerna’s GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates –

– Each Company to Retain Rights to Co-Develop and

Co-Commercialize Product Candidates –

– Dicerna to Receive Upfront Payment of USD 175 Million and

Equity Investment of USD 50 Million –

– Dicerna is Eligible to Receive an Additional USD 75 Million Over the First Three Years, Plus Up to USD 357.5 Million per Target in Potential Milestone Payments, and Royalties on Product Sales –

– Dicerna to Host Conference Call Today at 8:00 a.m. ET –

LEXINGTON, Mass., & BAGSVÆRD, Denmark--(BUSINESS WIRE)-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) and Novo Nordisk A/S 


 https://dicerna.com/ 


 https://www.businesswire.com/news/home/20191118005269/en/ 


  novonordisk.com 

Vertex and Molecular Templates Establish Collaboration

image293

 

Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

Mon November 18, 2019 7:00 AM|GlobeNewswire|About: MTEM 

 

-Molecular Templates (MTEM) to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales-

BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc.


 https://mtem.com/ 


 https://www.vrtx.com/ 


 https://mtem.com/etb-platform/pipeline/ 

ORION-10 Study of Inclisiran

image295

 

The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

Sat November 16, 2019 10:45 AM|Business Wire|About: MDCO

- Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD)

- ORION-10 study affirmed inclisiran’s excellent safety profile, including no treatment-related liver or renal abnormalities

- Results presented today during late-breaking science session at American Heart Association annual meeting in Philadelphia

- The Medicines Company (MDCO) to host investor conference call and webcast on Monday, November 18, 12:00 pm EST

PHILADELPHIA--(BUSINESS WIRE)


 https://www.themedicinescompany.com/ 


 https://seekingalpha.com/news/3520048-medicines-company-2-percent-premarket-positive-inclisiran-data 



BiotechVortex™

Editas Medicine and Celgene Corporation

image296

 

Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases

Tue November 12, 2019 7:00 AM|GlobeNewswire|About: EDIT

The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells

Editas Medicine (EDIT) to receive a $70 million payment and may be eligible for future milestone and royalty payments

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc., a leading genome editing company, today announced an amended collaboration with Celgene Corporation (Nasdaq: CELG) 



CABOMETYX® (cabozantinib)

image297

 

Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma

Tue November 12, 2019 8:02 AM|Business Wire|About: EXEL

– Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial –

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (NASDAQ:EXEL)


 https://www.businesswire.com/news/home/20191112005303/en/ 


 https://ir.exelixis.com/news-releases/news-release-details/exelixis-partner-ipsen-announces-health-canadas-approval-0 



 https://www.ipsen.com/partnering/ 


 https://www.exelixis.com/ 



Celgene inks second collaboration deal with Skyhawk

image298

 

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

Tue November 12, 2019 9:00 AM|PR Newswire|About: CELG

Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets. 

Skyhawk to receive $80 Million upfront payment and is eligible for potential milestone payments and royalties.

WALTHAM, Mass., Nov. 12, 2019 /PRNewswire/ -- Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered into a second global strategic collaboration with an affiliate of Celgene Corporation (CELG)


 https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-a-second-multi-target-collaboration-agreement-with-celgene-to-discover-and-develop-novel-small-molecules-that-modulate-rna-splicing-300956283.html 

Exicure (NASDAQ:XCUR) will collaborate with Allergan (NYSE:AGN)

image299

 

Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

Thu November 14, 2019 7:00 AM|Business Wire|About: AGN, XCUR

- Exicure (XCUR) to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones

- Exicure to Host Conference Call Today at 8:30am ET/7:30am CT

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc., (NASDAQ:XCUR)


 https://www.businesswire.com/news/home/20191114005106/en/ 


 https://seekingalpha.com/news/3519164-exicure-teams-allergan-hair-loss-disorders-shares-24-percent-premarket 


 Allergan is focused on driving innovation in four core therapeutic areas. As part of our approach to delivering innovation for better patient care, we have built one of the broadest pharmaceutical and device research and development pipelines in the industry. 

 https://www.allergan.com/research-and-development/pipeline 


BiotechVortex™

New Global R&D Centre, AI Innovation Centre and a joint investment fund with CICC

image302

 

AstraZeneca announces three large-scale initiatives in China to advance global medicine research and development

PUBLISHED6 November 2019

New Global R&D Centre, AI Innovation Centre and a joint investment fund with CICC to underpin next phase of growth and support transformation of healthcare in China


 https://seekingalpha.com/news/3515077-astrazeneca-launches-1b-china-investment-fund 

Biogen Inc. (BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd.

image303

 

Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

Wed November 6, 2019 7:30 AM|GlobeNewswire|About: BIIB

  • Biogen to gain exclusive commercialization rights to two new ophthalmology biosimilars referencing Lucentis and Eylea in the U.S., Canada, Europe, Japan and Australia

  • Will provide Biogen with commercialization rights for its current anti-TNF biosimilars portfolio in China, adding to its strategic presence in this priority market
     
  • Includes an option to extend the term of its existing European commercial agreement

CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd.


 https://www.samsungbioepis.com/en/index.do 


 https://investors.biogen.com/news-releases/news-release-details/biogen-expand-biosimilars-portfolio-and-gain-access-additional 

Antengene Corporation today announced it has a licensing agreement with AstraZeneca (LSE/STO/ AZN

image304

 

Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

Wed November 6, 2019 11:31 AM|PR Newswire|About: AZN, CELG 

 SHANGHAI and LONDON, Nov. 6, 2019 /PRNewswire/ -- Antengene Corporation today announced that it has entered into a licensing agreement with AstraZeneca (AZNCF) (LSE/STO/NYSE: AZN)  


 https://www.prnewswire.com/news-releases/antengene-corporation-announces-exclusive-worldwide-license-to-develop-and-commercialize-azd0364-300953003.html 

Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab

image306

 

Aduro Biotech Announces Presentation of Results from First-in-Human Phase 1 Study of Anti-CD27 Agonist as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 34th Annual Meeting

Fri November 8, 2019 4:05 PM|GlobeNewswire|About: ADROQ3: 11-07-19 Earnings SummaryEPS of $-0.26 misses by $-0.02 Revenue of $4.8M (56.68% Y/Y) beats by $0.76M

BERKELEY, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,


  (see www.clinicaltrials.gov, identifier NCT03396445). 


 https://investors.aduro.com/news-releases/news-release-details/aduro-biotech-announces-presentation-results-first-human-phase-1?field_nir_news_date_value[min]=2019 


Galectin Therapeutics Reaches Agreement w Siemens Healthineers - Collaborate on NASH &Liver Fibrosis

image307

 

Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis

Mon November 11, 2019 9:47 AM|GlobeNewswire|About: GALT

NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in medical technology, in nonalcoholic steatohepatitis (NASH) and liver fibrosis.


 https://clinicaltrials.gov/ct2/show/NCT02462967?lead=galectin&phase=12&draw=2&rank=1 


 https://galectintherapeutics.com/ 





BiotechVortex™

AMGN, BGNE

image308

 

BeiGene Announces Global Strategic Oncology Collaboration with Amgen

Thu October 31, 2019 4:00 PM|GlobeNewswire|About: AMGN, BGNE 


 

• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China 

• Companies to Jointly Develop 20 Amgen (AMGN) Oncology Pipeline Assets, with BeiGene Responsible for Development and Commercialization in China as Part of the Global Development Plan

• Amgen to Purchase Approximately $2.7 Billion of BeiGene Shares  

• BeiGene to Hold Analyst and Investor Call on Thursday, October 31 at 8:00 p.m. ET

CAMBRIDGE, Mass. and BEIJING, China, Oct. 31, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE) and Amgen 


 https://www.beigene.com/science-and-product-portfolio/pipeline 


 https://www.amgen.com/media/news-releases/2019/10/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china/ 


 https://seekingalpha.com/news/3512709-amgen-teams-beigene-cancer 


 

Amgen (AMGN) Announces Collaboration with BeiGene - Slideshow

Nov. 11, 2019 1:30 PM ET | About: Amgen Inc. (AMGN) 

 https://seekingalpha.com/article/4305471-amgen-amgn-announces-collaboration-beigene-slideshow 

Gilead Sciences, Inc. (GILD) Galapagos NV (GLPGF)

image309

 

Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

Fri November 1, 2019 4:01 PM|GlobeNewswire|About: GLPG

Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ: GILD), delivered an exercise notice to Galapagos NV (GLPGF) (Euronext & NASDAQ: GLPG) 


 https://seekingalpha.com/news/3513251-gilead-stake-galapagos-25_1-percent 



SYK

image310

 

Stryker announces definitive agreement to acquire Wright Medical

Mon November 4, 2019 7:00 AM|GlobeNewswire|About: SYK 

 Kalamazoo, Michigan, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Stryker (SYK


 https://www.stryker.com/ 

cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies

image311

 

Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

Tue November 5, 2019 7:00 AM|Business Wire|About: TAK

− Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021

− Potential to be the First CAR Cell Therapy Approved for Outpatient Administration

HOUSTON & OSAKA, Japan--(BUSINESS WIRE)-- The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK) (“Takeda”) 


 https://www.businesswire.com/news/home/20191105005250/en/ 


 https://www.takeda.com/ 


 https://www.mdanderson.org/cancermoonshots/cancer-types/Leukemia_CLL.html 


 https://www.mdanderson.org/cancermoonshots/cancer-types/b-cell-lymphoma.html 


 https://www.mdanderson.org/cancermoonshots/research_platforms/adoptive-cell-therapy.html 


 https://www.mdanderson.org/ 

BiotechVortex™

WALGREENS, SUSAN G. KOMEN AND LLS COLLABORATE TO SUPPORT RESEARCH

image314

 

Walgreens, Susan G. Komen and The Leukemia & Lymphoma Society Collaborate to Support Research in Tough-to-Treat Cancers and Increase Access to Care

Tue October 22, 2019 9:00 AM|Business Wire|About: WBA

$25M, multi-year commitment builds on Walgreens (WBA) efforts to improve the health and well-being of people living with cancer nationwide

DEERFIELD, Ill. & DALLAS & RYE BROOK, N.Y.--(BUSINESS WIRE)-- Walgreens announced today a new collaboration with Susan G. Komen and The Leukemia & Lymphoma Society 


 https://www.businesswire.com/news/home/20191022005311/en/ 


 https://www.lls.org/lls-us-hq/news/walgreens-susan-g-komen-and-lls-collaborate-to-support-research-in-tough-to-treat-cancers-and-increase-access-to-care?news=News%20Releases&newsid=12355 


 https://ww5.komen.org/ 

Abbott's Alinity s Solution

image315

 

The Australian Red Cross Blood Service Selects Abbott's Alinity s Solution for Blood and Plasma Screening

Mon October 21, 2019 9:00 AM|PR Newswire|About: ABT    PR Newswire

ABBOTT PARK, Ill., Oct. 21, 2019 /PRNewswire/ -- Abbott (ABT)


 https://www.prnewswire.com/news-releases/the-australian-red-cross-blood-service-selects-abbotts-alinity-s-solution-for-blood-and-plasma-screening-300941474.html 



CNP-101/TAK-101, immune modifying nanoparticle to induce tolerance to gluten in patients with celiac

image316

 

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

Tue October 22, 2019 1:00 AM|Business Wire|About: TAK

− Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease

− Takeda (TKPHF) acquires exclusive global license to investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease

OSAKA, Japan & CHICAGO--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”)


 https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/symptoms-causes 


 https://www.takeda.com/newsroom/newsreleases/2019/takeda-acquires-license-for-first-in-class-celiac-disease-therapy-from--cour-pharmaceuticals-following-positive-phase-2a-proof-of-concept-study/ 

QuantiFERON®-TB Gold Plus (QFT®-Plus)

image317

 

QIAGEN’s QuantiFERON®-TB Gold Plus Test Added to the Global Drug Facility Catalog for Public Health Efforts

Tue October 29, 2019 5:05 PM|Business Wire|About: QGEN

  • QIAGEN expands market for gold standard latent TB test to help developing countries fight TB
  • WHO-endorsed test to support communities with the highest need
  • First demonstration of QuantiFERON®-TB Access at the Union World meeting in India

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (QGEN)


 https://www.businesswire.com/news/home/20191029005850/en/ 


 https://www.who.int/tb/publications/global_report/en/ 


 http://www.stoptb.org/gdf/ 

ABBV will advance= potentiator into clinical development for use in treatments cystic fibrosis (CF)

image318

 

AbbVie Announces Collaboration with Cystic Fibrosis Foundation

Thu October 24, 2019 8:00 AM|PR Newswire|About: ABBV

NORTH CHICAGO, Ill., Oct. 24, 2019 /PRNewswire/ -- AbbVie (ABBV)


 https://www.prnewswire.com/news-releases/abbvie-announces-collaboration-with-cystic-fibrosis-foundation-300944388.html 

Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT

image319

 

Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT

Wed October 30, 2019 6:59 AM|Business Wire|About: BMY

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) (NYSE:BMY) and LabCentral


 https://www.businesswire.com/news/home/20191030005268/en/ 


 https://www.carminetherapeutics.com/ 

BiotechVortex™

ILMN, QGEN

image320

 

Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

Mon October 7, 2019 4:05 PM|Business Wire|About: ILMN, QGEN

Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making

SAN DIEGO & HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- Illumina, Inc. (ILMN) and QIAGEN N.V. (QGEN)


image321

 

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence

October 1, 2019 | Microsoft News Center


 

  • Multiyear alliance underpins the Novartis commitment to leverage data & artificial intelligence (AI) to transform how medicines are discovered, developed and commercialized
  • Novartis to establish AI innovation lab to empower its associates to use AI across the business
  • Joint research activities will include co-working environments on Novartis Campus (Switzerland), at Novartis Global Service Center in Dublin, and at Microsoft Research Lab (UK) – starting with tackling personalized therapies for macular degeneration; cell & gene therapy; and drug design

Basel, and Redmond, October 1, 2019

Valiant® TAAA Stent Graft System

image322

 

Medtronic Receives FDA Breakthrough Device Designation for Developing Stent Graft System to Treat Thoracoabdominal Aortic Aneurysm

Tue October 8, 2019 10:00 AM|GlobeNewswire|About: MDTGlobeNewswire

DUBLIN, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT)

BLUE NVO

image323

 

bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

Wed October 9, 2019 8:00 AM|Business Wire|About: BLUE

CAMBRIDGE, Mass. and BAGSVÆRD, Denmark--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO)

Abbott (ABT) and Tandem Diabetes Care (TNDM)

image324

 

Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management

Tue October 15, 2019 8:00 AM|PR Newswire|About: ABT, TNDMPR Newswire

ABBOTT PARK, Ill. and SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Abbott (ABT) and Tandem Diabetes Care (TNDM)

Living With Diabetes

image325

Roche Partners with iHeartMedia to Present 'iHeartCountry One Night For Our Military' Concert to Bring Further Awareness of The Impact Diabetes Has On The Nation's Veteran Population

Mon October 14, 2019 8:00 AM|PR Newswire|About: CHGCY, IHRT, RHHBY

-- Event Will Broadcast Nationwide On Veteran's Day From The Country Music Hall of Fame, Honoring The One In Four Veterans Living With Diabetes In The U.S.

PR Newswire

INDIANAPOLIS, Oct. 14, 2019 /PRNewswire/ -- Roche (ROCM) (SIX: RO, ROG; OTCQX: RHHBY)


 https://www.prnewswire.com/news-releases/roche-partners-with-iheartmedia-to-present-iheartcountry-one-night-for-our-military-concert-to-bring-further-awareness-of-the-impact-diabetes-has-on-the-nations-veteran-population-300937249.html 


 https://www.research.va.gov/pubs/docs/va_factsheets/Diabetes.pdf 

BiotechVortex™

Pfizer (PFE)

image326

 

Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina

Wed August 21, 2019 10:00 AM|Business Wire|About: PFE

NEW YORK--(BUSINESS WIRE)-- Pfizer (PFE

T-Cell Receptor Engineered T-cell Therapy (TCR-T) programs

image327

 

Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies

Aug 28, 2019 | News, USA

  • Celgene Secures Exclusive Options to Three Immatics TCR-T Targets
  • Immatics to Receive $75 Million Upfront Payment and May Be Eligible for Future Opt-in Exercise, Milestone and Royalty 
  • Immatics Retains Options to Co-Develop or Co-Fund Certain Licensed Products

 Houston, Texas and Tuebingen, Germany, August 28, 2019 – Immatics Biotechnologies GmbH 

CIVO™ multiplexed intratumoral microdosing platform,

image328

 

Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology

Tue August 27, 2019 8:00 AM|PR Newswire|About: BMY

SEATTLE, Aug. 27, 2019 /PRNewswire/ -- Presage Biosciences

smart insulin pens into Continuous Glucose Monitoring (CGM) devices

image329

 

Medtronic and Novo Nordisk Enter Agreement to Provide Integrated Digital Solutions for People with Diabetes

Mon September 16, 2019 3:00 AM|GlobeNewswire|About: MDTGlobeNewswire

DUBLIN and BAGSVÆRD, Denmark, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) (NYSE:MDT), and Novo Nordisk A/S


AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR

image330

 

Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine

Mon September 9, 2019 7:30 AM|Business Wire|About: ALXN, BBIO, EIDX

- Eidos grants Alexion (ALXN) exclusive license to develop and commercialize AG10 in Japan -

- Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to initiate in second half of 2019 -

- Agreement expands Alexion’s amyloidosis portfolio -

- Eidos to receive upfront payment of $25 million and equity investment of $25 million, with potential for additional Japanese-based milestone- & royalty-dependent payments -

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and BridgeBio Pharma, Inc. (BBIO)’s (NASDAQ:BBIO) subsidiary Eidos Therapeutics, Inc. (EIDX) (NASDAQ:EIDX) 

FreeStyle Libre technology with Sanofi′s insulin dosing information for future smart pens,

image331

 

ABBOTT AND SANOFI PARTNER TO INTEGRATE GLUCOSE SENSING AND INSULIN DELIVERY TECHNOLOGIES TO HELP CHANGE THE WAY DIABETES IS MANAGED

- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin

- Two world leaders in diabetes work together to drive meaningful change in care


 ABBOTT PARK, Ill. and PARIS, Sept. 16, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) and Sanofi  

BiotechVortex™

Innovation-Lounge with focus on diabetes

image332

 Lilly Germany kicks off Innovation-Lounge with focus on diabetes

by LillyPad 30/07/2019 

 By Dr. Stefanie Beck, Government Affairs Manager Lilly Germany. 

iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps

image333

 

  • LILLY, EVIDATION HEALTH AND APPLE STUDY SHOWS PERSONAL DIGITAL DEVICES MAY HELP IN THE IDENTIFICATION OF MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER'S DISEASE DEMENTIA

Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia

08/08/2019Download PDF

INDIANAPOLIS, Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL)


 https://seekingalpha.com/pr/17597726-lilly-evidation-health-apple-study-shows-personal-digital-devices-may-help-identification 

Optune® Tumor Treating Fields

image334

 

China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China

Mon August 12, 2019 7:30 AM|Business Wire|About: NVCR, ZLAB

SHANGHAI & ST. HELIER, Jersey--(BUSINESS WIRE)-- Zai Lab Limited (ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NVCR),


 http://www.zailaboratory.com/products/index.aspx 

Financial Time - Novartis (NVS) to file 50 applications for drug approvals in China by 2023

image335

Novartis bets big on China, 50 new drug applications expected by 2023

Aug. 12, 2019 9:36 AM ET|About: Novartis AG (NVS)|By: , SA News Editor  

Insulet Corporation (PODD)

image336

 

Insulet Omnipod DASH™ System Mobile Apps Now Available for iOS Devices

Fri August 9, 2019 10:05 AM|Business Wire|About: PODD 

Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide)

image337

 

China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Fri August 9, 2019 8:30 AM|Business Wire|About: GILD

-- Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks --

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD

 

Québec Provides Access to Biktarvy® for the Treatment of HIV

Thu August 15, 2019 8:00 AM|Canada Newswire|About: GILD 

 MISSISSAUGA, ON, Aug. 15, 2019 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) 

 https://seekingalpha.com/pr/17604746-quebec-provides-access-biktarvy-treatment-hiv 

seeking biotech alpha partnerships

Bristol-Myers Squibb & Tsinghua University

image338

 Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer 

Abbvie & Rice University

image339

 AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology 

Johnson & Johnson & Boston University

image340

Johnson & Johnson and Boston University Announce a New Alliance Focused on Tackling Lung Cancer 

Amgen And Cedars-Sinai

image341

Amgen And Cedars-Sinai Partner For Improved Healthcare Quality

Thu July 19, 2018 4:00 PM|PR Newswire|About: AMGN 

jlabs-shanghai

image342

Shanghai Lung Cancer Innovation QuickFire Challenge